|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/17 | |
| A61P 25/02 | |||
| A61K 38/00 |
| (11) | Patento numeris | 2061485 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 07804199.3 |
| Europos patento paraiškos padavimo data | 2007-09-10 | |
| (97) | Europos patento paraiškos paskelbimo data | 2009-05-27 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2012-08-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/GB2007/003401 |
| Data | 2007-09-10 |
| (87) | Numeris | WO 2008/029167 |
| Data | 2008-03-13 |
| (30) | Numeris | Data | Šalis |
| 0617734 | 2006-09-08 | GB |
| (72) |
HAMER, John, GB
|
| (73) |
Varleigh Immuno Pharmaceuticals (VIP) Ltd,
Landmark Fiduciaire (Suisse) SA 6 Place des Eaux-Vives Case Postale 3461, 1211 Geneva 3,
CH
|
| (54) | EV576 peptides for use in the treatment of Guillain Barré syndrome |
| EV576 peptides for use in the treatment of Guillain Barré syndrome |